Kingsview Wealth Management’s Immunic IMUX Stock Holding History

Kingsview Wealth Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$14K	–	916
2022 Q4	$14K	Buy	+1,000	New	+$27.3K	﹤0.01%	837

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Kingsview Wealth Management's IMUX Position: Q1 2023 in Review

Kingsview Wealth Management sold out of Immunic (IMUX) in Q1 2023, closing a stake of 1,000 shares — an estimated $14K sold.

Kingsview Wealth Management first reported a position in IMUX in Q4 2022 and held it in 1 quarter. The position peaked at $14K in Q4 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2023.

Kingsview Wealth Management reported no remaining Immunic position as of Q1 2023 after selling out during the quarter.
Kingsview Wealth Management sold 1,000 Immunic shares in Q1 2023, an estimated $14K.
Kingsview Wealth Management first reported a position in Immunic in Q4 2022 and held it in 1 quarter.
Kingsview Wealth Management's Immunic position peaked at $14K in Q4 2022.
59 funds tracked by Wall St. Rank held Immunic as of Q1 2023.

Based on Kingsview Wealth Management's 13F filing for Q1 2023, filed 15 May 2023.